New
HealthMore in Health→
Pelacarsen Lowers Lipoprotein(a) Without Cutting Heart Events
Key Takeaways
- The randomized trial enrolled 8,322 patients with established cardiovascular disease and elevated lipoprotein(a).
- Pelacarsen reduced median lipoprotein(a) to 64.4 nmol/L at 12 months versus 233.4 nmol/L with placebo.
- Major adverse cardiovascular events occurred in 12.3% of pelacarsen patients and 12.1% of placebo patients over median 4.7-year follow-up.
DE
DT Editorial Team··via medicalxpress.com